While small-count MBL rarely progresses to CLL, substantial-count MBL progresses to CLL demanding therapy in a price of 1% to 2% per annum. High-depend MBL is distinguished from Rai 0 CLL based on if the B-cell depend is higher than or under 5 × 109/L. Though individuals with the two higher-count MBL and CLL Rai phase 0 are at improved hazard of i